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lUTRODUCTION 
Proteolytic enzymes are of universal occurrence in 
living systems and perform a variety of functions. Depending 
upon the specificity of these enzymes they have been 
classified into four classes namely serine, thiol, aspartic 
and metalloproteinases; out of these Thiol proteinases play 
very important role in the degradation of intracellular 
proteins in vivo { 1-4). 
Cathepsins are thiol enzymes, present in lysosomes, 
which are involved in intracellular digestion of proteins. 
The best characterized of these thiol proteinases are 
cathepsins B (5), H(6) and L(7). They are evolutionary 
related to papain and are responsible for much of the bulk 
turnover of proteins. Other cellular thiol endopeptidases 
+ + 
present in lysosomes include the cytosolic Ca dependent 
proteinases the calpains (8). Lysosomes also contain thiol 
exopeptidases such as dipeptidyl peptidase I that completes 
degradation of proteins by their rapid action on 
oligopeptides (9). 
Proteolysis within the lysosomal system is initiated by 
these endopeptidases, cleaving bonds within the peptide 
chains and is completed by exopeptidase. 
These enzymes can inactivate some native enzymes such 
as aldolase (10), glucokinase (10), pyruvate kinase (10), 
fructose 1,6 bisphosphatase (11), glucose 6 phosphate 
dehydrogenase (12) and some other enzymes. They also play 
significant role in hormone metabolism (13) and in the 
cleavage of certain precursor proteins generating their 
active forms such as proinsulin to insulin (14), albumin from 
proalbumin (15) and parathyrin from proparathyrin (16). Such 
proteolytic conversions commonly require limited proteolysis 
on the C-terminal side chain. These processes take place in 
golgi apparatus. 
Cathepslns also play very Important role In 
inflammatory processes and in pathogenesis of diseases such 
as rheumatoid arthritis and pulmonary emphysema which occurs 
due to proteolysis of lung structural proteins by Cathepsin 
G, a proteinase released from polymorphonuclear leucocytes 
(17-19). In arthritis and joint inflammation there is 
breakdown of extracellular proteoglycans, the core protein 
of proteoglycans is susceptible to the action of cathepsin B 
which produces peptide fragments containing one to several 
polysaccharide chains (20). Inflammatory reactions of 
whatever origin are accompanied by an increase of lysosomal 
membrane permeability which provoke at the tissue level 
releasing lysosomal enzymes cathepsins (21). The enzymes may 
come from injured connective tissues or from deteroid 
polymorphonuclear cells. In some pathological conditions like 
ischaemia, hypervitaminosis and exposure to ultra violet 
radiations lysosomal enzymes are released in extracellular 
space and produce extensive damage to the extracellular 
matrix (22,23). Cathepsin B secreted from human pancreatic 
cancer cells is a variant types and may play important role 
in pancreatic cancer through destruction of the surrounding 
extracellular matrix by its proteolytic activity (24). 
Cathepsins have also been shown to produce immunoglobulin 
fragments by acting on human IgG. These fragments act as 
autoantigens which leads to development of inflammation and 
polymorphonuclear chemotaxis (25). 
Exact mechanism of regulation of proteolytic activity 
is obscure to date. However evidences suggest that these 
enzymes effect the degradation of proteins destined for 
secretion by fusion of secretary vesicles with lysosomes or 
by their inclusion directly within the secretory vesicles. 
The materials which are accummulated inside the lysosomes in 
different modes are degraded by these lysosomal enzymes at 
acid pH. Systematic studies on proteolysis revealed that the 
process is under biological control acting at the level of 
protein synthesis or mediated through protein inhibitors. 
THIOL PROTEINASE INHIBITORS 
Specific thiol proteinase inhibitors (cystatins) 
together with plasma protein cK/ macroglobulin control the 
2 
activity of these proteolytic enzymes. c<, macroglobulin is a 
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general endopeptidase present in serum, which inhibit 
proteinases of all classes (24). The purified protein is 
composed of a tetramer of identical subunits of molecular 
weight 185,000 linked in pairs by disulphide bonds. Two 
pairs associated by non covalent binding form the native 
tetramer molecules (26-36). The subunits found to contain 
approximately 1450 amino acids with amino terminal serine and 
carboxyterminal alanine (25). 
Cystatins are the specific thiol proteinase inhibitors 
which play significant role in controlling the activity of 
thiol proteinases like cathepslns B, H and L. The name 
cystatin was coined by Barrett (37) for such proteinase 
inhibitors which specifically inhibit thiol proteinases. The 
activity of cystatin was first detected by Finkelstadt in 
the year 1957 (38) as a heat stable inhibitor of cathepsin B 
and dipeptidyl peptidase I in rat liver cytosol. Then 
Whitakar and coworkers in the year 1968 (39) partially 
purified a protein from chicken egg white that inhibited 
ficin and papain, further work by Kielova and Tomasek (1974, 
1975) (40) established that the protein also inhibits 
Cathepsin B and dipeptidyl peptidase I. 
OCCURRENCE OF CYSTATINS 
Protein inhibitors of thiol proteinases are widely 
distributed in mammalian tissues (41) plants (42), human 
beings (43) and in microorganism (44). In higher animals and 
man cystatins have been isolatad from plasma derived 
interstitial fluids (45), Cellular material (46) and from 
blood plasma. Presence of thiol proteinase inhibitor 
(cystatin) has also reported in various mammalian tissues 
e.g. human liver (47), human skin (48) human spleen. Human 
brain and Human heart (49-58). 
CYSTATIN SUPERFAMILY 
All cystatins specifically inhibit thiol proteinases, 
but differ widely in molecular properties and biological 
distribution. They have been found to be evolutionary related 
forming the cystatin superfamily. The cystatin superfamily 
comprises a diverse group of thiol proteinase inhibitors 
which are present in a variety of tissues and body fluids. 
Based on the complexity of the molecule, cystatins have been 
categorized into three classes. Stefins (type I) represent 
the simplest form and are principally found in tissues. 
Kininogens (type III) represent the most complex form of the 
cystatins and are present in blood plasma. Type II cystatins 
represent an intermediate class and are found in both tissues 
and body fluids, including saliva. These are the families of 
closely related proteins, which have about half of their 
amino acid residues in common. 
Family 1(Type I) 
Family 1 comprises of cystatin A and B. These cystatins 
consisted of about 110 amino acid residues (MW 11,000) with 
no disulphide bonds or carbohydrate content e.g. cystatin A 
has been isolated from human skin (42) and liver (43). 
Cystatin B has been isolated from human skin (42) and spleen 
(44). They have been named as stefins. They may contain 
cysteine residues, which play an important role in 
biological activity. 
Cystatin A 
Cystatin A was first discovered by Fraki (42) as an 
inhibitor of cathepsin B in human skin which was isolated 
and further characterized as acid thiol proteinase inhibitor 
(ATPI). Later on the inhibitor was purified from blood 
leucocytes (58) and was named as stefin. Green et al (59) 
have characterized two thiol proteinase inhibitors from 
human liver and skin the more acidic of these was Initially 
referred to as thiol proteinase inhibitor A. Later on, it was 
renamed as cystatin A. The second component isolated from 
liver was named as cystatin B. Data for the composition of 
cystatin A is summarized in table 1. 
Cystatin A occurred as multiple forms with pi 
range 4.5 - 5.0. It is usually stable to condition that 
denature most proteins (60). It is stable to boiling 
for 20 minutes and also to treatment with 5.07o 
trichloroacetic acid, 4M NH OH and 20 mM trisodium 
4 
phosphate. The inhibitor was precipitated and Inactivated by 
1007o trichloroacetic acid. Cystatin A specifically inhibits 
papain, ficin and cathepsin B,H and L (table 2). 
Cystatin B 
Cystatin B has been detected in various human tissues 
by Lenney et. al (61) and Jarvinen et. al (44). This cystatin 
has been found primarily in lymphocytes and in liver (62) 
as neutral thiol proteinase inhibitor (NTPI). It has been 
reported that cystatin B Is more widely distributed in cells 
than cystatin A with the probable exceptions of 
polymorphonuclear leucocytes. Cystatin B has been isolated in 
three multiple forms (59). It is heat stable inhibitor and it 
o 
could be incubated for 10 minutes at 80 C without loss of 
activity (59). Composition and specificity of cystatin B has 
beer, given in table 1 and 2 respectively. 
Family 2 (Type II) 
This family includes cystatin C, S, N and chicken 
cystatin. They are made up of about more than 115 amino acid 
residues (MW 13,000) and contain two disulphide bonds 
towards the carboxyterminal. This family includes chicken egg 
white cystatin (39), cystatin S isolated from human saliva 
(63-64) and cystatin C isolated from cerebrospinal fluid 
(65), Urine (66), normal serum and seminal plasma (66). 
Obviously they may originate in cells and may function 
intracellularly too. 
Cystatin C 
Cystatin C is a very basic protein, first isolated in 
human cerebrospinal fluid and was named as post-r-globulin 
due to •/ -electrophoretic mobility. At the same time, it was 
found in urine (66) from patients with renal failure and in 
ascitic fluid and pleural fluid (66). The amino acid sequence 
of r-trace was the first sequence of a cystatin to be 
determined. The identification of r-trace as a cystatin was 
confirmed and extended by Barrett et. al. (67) who called 
the protein as Cystatin C. The protein was later found In 
saliva and normal serum and in seminal plasma (54). Its 
concentration was found to be ten times higher than normal 
in serum of patients suffering from autoimmune diseases (58) 
such as lupus erythematosus and glomerulonephritis. The 
concentration of the inhibitor in seminal plasma was found 
to be 50 ug/ml which was approximately 36-fold higher than 
in normal blood plasma (68). The relatively high concentration 
of cystatin C in cerebrospinal fluid compared with blood 
plasma has been suggested to be an indication of cystatin C 
production in the central nervous system (69). pi values of 
the inhibitor was found to be 8.0 - 8.5 (70). Degradation of 
N-terminus occurs during storage to produce forms laking one 
or more basic residues and therefore of lower pi values 
(70). 
Cystatin C specially inhibits papain and cathepsin 
B,H and L (table 2). Composition of cystatin C is given in 
table 1. 
Cystatin S & N 
This inhibitor was first isolated from saliva and was 
named as salivary acid proteinase inhibitor (SAPI) which was 
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renamed as cystatin S (63) and found to have 54% and 41% 
sequence homology with cystatin C and chicken cystatin 
respectively. Cystatin S has also been isolated from 
submaxillary,, submandibular and sublingual glands (64). 
It was also reported in tears (64), serum, urine, 
bile, pancreas and bronchus (64). Cystatin S has a pi of 
4.68. Cystatin S (71) like other cystatins is very stable to 
extremes of pH and heat. Composition of this inhibitor 
indicates it to be acidic in nature (table 1). The name N was 
given to neutral form of cystatin isolated from human saliva 
(63-64). Specificity of these inhibitors given in table 2. 
Chicken Cystatin 
hicken cystatin was isolated from egg white which 
inhibited ficin, papain, cathepsin B and dipeptidyl peptidase 
I. It also inhibited cathepsin H and L (Table 2). Later on it 
was reported in the serum of both male and female chickens 
and in chicken muscle cells, chicken cystatin was present at 
about 80 ug/ml in egg white. It was found to be stable to 
heat and could be boiled for 30 minutes without much loss of 
activity, but was unstable to freezing or freeze drying, 
unless in the presence of 20% glycerol or buffered at pH 7.5. 
High stability at alkaline pH was reported by Anastasi et al 
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(72). Although Fossum and Whitakar (39-40) found greater loss 
of activity at pH 9.0 than pH 4.0 during boiling. Chicken 
cystatin was found to be a basic protein (Table 1). 
Family 3 (Type III) 
The cystatlns of this family are named as kininogens. 
They are exclusively found in serum or plasma (43). They have 
about 427 amino acids in total. They have more than two 
disulphide bonds. The kininogens are larger precursor 
molecules of the vasoactive kinins, is a nonapeptide that is 
able to diminish blood pressure induces smooth muscle 
contraction and provoke pains (74). It is released after 
cleavage of precursor protein molecules i.e. kinlnogen by 
proteolytic enzymes like Kallikrein and Trypsin (74). Human 
plasma contains at least two distinct kinds of kininogens 
that differ in their molecular weight e.g. a high molecular 
weight kininogen (HMWK) and low molecular weight kininogen 
(LMWK). They are single chain glycosylated proteins. Both 
kininogens (HMW and LMW) are structurally similar, having a 
heavy chain of about 381 amino acid residues kinin segment of 
9 amino acid residues and a light chain. They have identical 
heavy chains preformed at N-terminus and the consecutive 
kinin segments, but differ considerably in their light chain 
at the C-terminus ( 75 ). 
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STRUCTURE OF CYSTATINS 
Hypothetical model of evolution of cystatins predicted 
that the variety of mammalian thiol proteinase inhibitors 
arose from a primordial stefin - type inhibitor (type 1) 
which represented the archetype inhibitors generating the 
kininogen, which contain three cystatin Type I like copies. 
Hence the cystatin superfamily of mammalian system was 
constituted by three distinct families with stefins, 
(Type I) cystatins (Type II) and kininogens (Type III) 
as their prototypes (76). 
Primary structure of cystatins 
The cystatins type I & II are polypeptides of 98 - 126 
amino acid residues with molecular weight values falling in 
the range 11,000 - 14,000. Cystatin A contains no cysteine 
residues but cystatin B contains one cysteine residue. Type 
II cystatins contain four cysteine residues forming two 
disulphide bonds and type III contains six cysteine residues 
with three disulphide bonds. Tryptophan was absent in type I 
cystatins but present in most of the other cystatins. 
It was reported that type I cystatins have N terminal 
methionine and most of them were acylated. This showed that 
signal peptides were absent. Methionine was not present at 
13 
the terminal of known type II cystatins. It was known that 
the type II cystatins have signal peptides upto 18 residues. 
Four residues were common Gly 9, Gin 53, Val 55 and Gly 
57 in all known sequences of cystatins. They were absent in 
light chain kininogen. The segment Gin 53 - Gly 57 was most 
highly conserved in the cystatin sequence and were considered 
to be of functional importance. The pentapeptide Gin - Val 
Val - Ala - Gly occurred in nine sequences and was speculated 
as the reactive site. The amino acid composition of cystatins 
of family I and II showed homology with each other (77-81). 
Secondary structure of cystatins (Type II) 
The secondary structure of only chicken cystatin has 
been worked out to some detail. The crystals of chicken 
cystatin were found to be suitable for collection of X-ray 
o 
diffraction data to 2.0 A resolution but until such data are 
available and in the absence of any other direct evidence as 
to the conformation of polypeptide chain of the cystatins, 
there are indirect indications of their folding. Circular 
dichroism and computer prediction of secondary structure from 
the sequence indicate that chicken cystatin has about 20% 
helix with the remainder being p structure (82). 
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Specificity and mechanism of Inhibition of cystatlns (Type II) 
Less is known about the evolution of proteinase 
inhibitors than of the proteinases themselves, because the 
molecular structure of these inhibitors is as yet unknown and 
their specificity is less pronounced than that of proteinases 
with which they combine. Cystatlns Inhibit plant enzyme 
papain, chymopapain, flcln, actlnidin and lysosomal cathepsin 
B,H and L. Bromelain a plant enzyme is not inhibited by 
cystatlns. The low molecular weight cystatlns do not inhibit 
calpains but low and high molecular weight kininogens of all 
species tested to date do inhibit calpaln (table 2) (57). 
They are reversible competitive inhibitors form tight complex 
even after the catalytic residues of the enzyme has reacted 
+ + 
with thiol blocking reagent such as iodoacetate or Hg . It 
is not known which part of the cystatin molecule binds the 
enzyme molecules. Some of the reported values of Kl are 
presented In (table 3). It can be seen that inhibition 
-13 
constant is as low as 5x10 M. Inhibition of cathepsin B 
tends to be weaker than that of papain, cathepsin H and L. 
Except with cystatin C which is strong inhibitor of cathepsin 
B. Inhibition of human cathepsin B by chicken cystatin is 
competitive with substrate. 
Kellova and Tomasik (85), Nlcklln and Barrett (84) 
made experiments to show that the chicken cystatin has a 
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single reactive site for the exopeptidase, dipeptldyl 
peptidase I, papain and cathepsin B. (83-85). 
Biological Aspects of Cystatins 
Generally cystatins control the unwanted proteolysis in 
cells. They defence against invading pathogens and parasites, 
many of which seem to use thiol proteinases for entering into 
the host body (86). A thiol proteinase produced by Leishmania 
spp is certainly inhibited by human cystatin A,B, C and 
kininogens and there is no reasons to doubt that the similar 
proteinases of many other pathogens are also susceptible 
(87). Cystatins act also as defence against viral infections, 
some viruses including common cold and poliomyelitis, code 
for proteins in the form of a single protein precursor that 
is. segmented by cleavage at specific site by a proteinase 
(88). Jarvinen et al (61) suggested that cystatins may 
contribute to the keratinization process and Hibino et ai 
(89-90) demonstrated their production in the upper spinous or 
granular cells (the cells that became keratinized) by using 
tritiated glycine as a label. It has been suggested that 
cystatin A is involved in differentiation of epidermis, on 
the basis of electron microscope immunolocalization 
work. 
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Production of autoantibodies to cystatin A have been 
demonstrated (92). In patients with autoantibodies, 687o 
suffered from forms of dermatitis, and 13% from psoriasis. 
Autoantibodies may be produced when the cystatin leaks into 
the blood stream following damage to the epidermis and 
dermis. 
Ohtani et al (93) purified cystatin A from normal and 
psoriatic skin and found the specific activity of the 
psoriatic to be half the normal values. Psoriasis may result 
from epidermal cells producing a less effective inhibitor. 
Cystatin C recently has suggested to be potent regulator in 
inflammatory reaction and the arthritis reaction in rabbit 
skin (94). 
One or two cases of AIDS showed profound alterations of 
dendritic reticulum cells revealed by localization of 
cystatin A (81). These could have been related to the 
destruction of lymphoid secondary follicles. 
A role of cystatin A and B has also been considered in 
connection with the control of turnover of myofibrils in the 
cytoplasm of muscle fibres. Muscular dystrophy is the result 
of accelerated degradation or retarded biosynthetic protein. 
The level of cystatins decreases in guinea pig with a 
muscular dystrophy induced by vitamin E deficiency (95). 
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The concentration of cystatin C may be elevated in the 
serum of patients suffering from autoimmune diseases, lupus 
erythematosus and glomerulonephritis (96). 
The cystatin may protect newly synthesized hormones 
from proteolysis by thiol proteinases, perhaps enzymes 
involved in their post-translational processing. 
Inhibitory activity for thiol proteinases was found to 
be higher in tumors than in normal tissues, and an inhibitor 
of MW 13,000 has been purified (97) from lung tumour tissues. 
Human malignant melanoma cell line released much more a 
cystatin like inhibitor into their culture medium than a 
variety of non-malignant cells. Cystatin C induced an 
inhibition of polymorphonuclear neutrophils, phagocytosis 
associated respiratory burst in response to opsonized zymogen 
particles (98). 
Bone hypercalcemia is administered by cystatin C (99). 
Blood serum level of cystatin C measures the glomerular 
filtration rate. 
Cystatin C deposition causes amyloid angiopathy and 
brain haemorrhage (100). Growth of 3T3 fibroblast cell was 
stimulated by the cystatin C (101). It was discovered that 
cystatin C is deposited in the wall of small blood vessels in 
the brain of Icelanders affected by genetic diseases that 
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lead to fatal cerebral haemorrhages (100). The cystatln C 
extracted from the amyloid deposits lacked the N-terminal 
decapeptide. However, Grubb (87) reported that concentration 
of cystatin C in cerebrospinal fluid of people affected by 
the hereditary amyloidosis was lower than normal down to 
about one third. Polio viruses and Rhino Viruses replication 
are inhibited by chicken egg - white cystatin (102). 
cystatins Type II are absent in human malignant serious 
ovirion carcinoma tissues sample. If it is present than Ki 
value for cathepsin B is higher indicating its low affinity 
(103). 
In this study cystatin type II has been isolated and 
purified from human placenta. Placenta is an independent 
organ showing the properties of an endocrine system, it 
produces one or more chorionic gonadotroph!ns, estrogens and 
progesterone. It is an oval and circular flat cake measuring 
6-8 inches (15-20 cm) in diameter, 3/4 - 1 inch ( 2-2 1/2) in 
depth at the centre, which is the thickest part and weighing 
about one pound. The margin is thinner firmer than the 
centre. The foetal surface is covered with a thin smooth 
membrane - the amnion, which can be readily stripped up to 
the insertion of the umbilical cord, which join the fetus 
with Placenta. 
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Functions of Placenta 
Placenta performs the function for respiration, food 
absorption and excretion. Waste products are carried to the 
terminal villi and are then passed out to maternal blood 
stream. Nutrient substance (derived from fats, proteins and 
carbohydrates), minerals, vitamins and oxygen in solution 
pass in the opposite direction. The volume of maternal blood 
in the intervillus space has been given as 30 - 300 ml. The 
area of the placenta in contact with maternal tissues has 
been estimated to be between 7-13 square meters. The smaller 
surface area and the sluggish circulation of the maternal 
blood in the placental sinuses account for the very low 
oxygen content of the foetal blood; but this is balanced by 
the relatively large amounts of foetal blood, its rapid 
circulation and the fact that foetal haemoglobin is capable 
of taking up large volumes of oxygen at low partial pressure. 
The oxygen requirements of the quescent foetus are low and 
there is no necessity for the foetus to produce its own 
heat. (106). 
There is of course normally no direct communication 
between foetal blood and the maternal blood. But they come to 
very close proximity during first half of the pregnancy. In 
the last half of the pregnancy blood streams are only 
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separated by a placental membrane 0.002 mm thick. The 
placental membrane has been shown to be unusual complex 
structure in the sense that it does not only function as the 
simple semipermeable membrane but it also varies in 
histological structure at the different times during 
gestation. The situation is complicated by the possibility 
that the membrane permits some simple substance to pass more 
readily then others, It Is also engaged in protein and 
carbohydrate metabolism and that it has the secretory 
function. The thinness of the membrane increases as the 
pregnancy advances. Proteins can cross the placenta as 
unaltered molecules, many antibodies such as antitoxins 
agglutinins can pass across the membrane. Presence of 
proteolytic, lipolytic, glycolytic and oxidising enzymes have 
been reported in placenta. (107-108). 
The specific placental proteins e.g. heat stable 
alkaline phosphatase, cysteine amino peptidase (oxytocinase), 
diamine oxidase (histaminase placental protein 5); with 
smaller peptides such as ACTH and the gonadotrophin releasing 
hormone (106-108) which are thoroughly characterized have 
been found to be analogous of proteins present in the normal 
adult i.e. sharing some chemical, immunochemical and 
biological features. There is no evidence for any difference 
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from the adult product. Excellent examples of analogues are 
provided by the protein hormones and alkaline phosphatase 
enzymes. The postulated function of placental proteins are of 
three types endocrine, metabolic and Immunological. The best 
recognized endocrine function of the placenta are those 
associated with its production of steroid hormones and their 
role in the maintenance of pregnancy. Functions of the 
majority of the placental protein has not been worked out 
yet. To date the experimental approach to elucidating 
biological function has concentrated on purification of 
several placental proteins (106-110). All placental proteins 
are synthesized by syncytlotrophoblast cells present in 
Placenta. Lysosomes present in cytotrophoblast and 
syncytlotrophoblast of placenta take part in Intracellular 
degradation of proteins. Cathepsins present in these 
lysosomes constitute an important group of both endo and 
exopeptidases Inhibited by cystatins.(111) 
Recently cystatin has been isolated from human 
placenta and has only been partially purified by M. Warwas 
and G. Sawlscki (112). Keeping in view the significance of 
placental tissue in human system and lack of information 
regarding the chemical structure and function of the cystatin 
in human placenta, we thought it worthwhile to isolate and 
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purify thiol proteinase inhibitor (cystatins) from this 
tissue, with an aim was to characterize the inhibitor 
systematically on physicochemical basis and also compare its 
properties with cystatins of the other human tissues. This 
might shed some light on the physiological function of 
cystatin type II in human placenta. Therefore in this study 
we have isolated and purified the cystatin to the extent of 
homogeniety and partially characterized it on the basis of 
molecular weight, pH, temperature and optical properties. 
EXPERIMENTAL 
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Materials 
Chemicals used for the present studies were obtained from the 
sources Indicated against their names 
Chemical Source 
1. Acrylamlde Sigma Chemical Co., U.S.A. 
2. Ammonium sulphate E. Merck Pvt. Ltd., India 
3. Blue dextran Pharmacia Fine Chemicals Sweden 
4. Bovine Serum albumin Sigma Chemical Co., U.S.A. 
5. Bromophenol blue B.D.H., England 
6. Casein Difco Laboratories, U.S.A. 
7. Coomassle brilliant Sigma Chemical Co., U.S.A. 
blue R-250 
8. Cysteine John Baker Inc., U.S.A. 
Hydrochloride 
9. Cytochrome C Sigma Chemical Co., U.S.A. 
10. Ethylenediaminetetra S.D. Fine chem. Pvt.,Ltd. 
acetic acid India 
11. Glycine Qualigens, Fine Chemicals 
India 
12. Glucose Glaxo, India 
13. N,N-Methylene B.D.H., India, 
bi sacrylamide 
14. Ovalbumin Sigma Chemical Co., U.S.A. 
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15. Papain 
16. Phenol 
17. Sephadex G50-80 
18. Sodium lauryl 
Sulphate 
19. Sucrose 
S.d. Fine Chem. Pvt. Ltd., 
India. 
Loba, Chem. India. 
Pharmamcia Fine Chemicals, 
Sweden 
Loba chemie, India 
Sisco Research Laboratories 
Pvt. Ltd., India. 
20. Tris (hydroxymethyl) Sigma Chemical Co., India, 
amino methane 
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Methods 
Placenta: Fresh human placenta was obtained from J.N.M. 
College Allgarh. Placenta was washed with cold distilled 
water. The membrane and cord was removed with scissors and 
the blood contaminations were removed by again washing the 
pieces thoroughly with distilled water. 
Column chromatography: A column of sephadex GCQ_QQ was 
prepared as recommended by Peterson and Sober (114) at 
Sephadex GcQ_on was allowed to swell in a suitable amount of 
distilled wacer for 6 hours in a boiling water bath. A 
previously cleaned glass column was mounted vertically and 
glass wool plugged alongwith beads at the bottom of the 
column. The column was filled to one third of its length with 
the operating buffer. The deaerated gel slurry was then 
gently poured into the column with the help of a glass rod. 
The column was left standing overnight. Flow rate was 
subsequently increased gradually with the help of a stop 
cock. After accomplishing a constant rate of flow higher 
than required for final elution, the column was adjusted to 
the required flow rate. The column was throughly washed with 
two bed volumes of operating buffer (0.02 M sodium phosphate 
buffer pH 6.0 with 0.15 M NaCl). In order to determine the 
26 
uniform packing and void volume (VQ) of the column, 2.0 ml 
of 2.0% (w/v) blue dextran was passed through the column. 
The buffer was carefully removed from the surface and protein 
sample applied. The volume of blue dextran or protein 
solution applied on the column was not more than 2-3.07o of 
the total bed volume of the column. 
Protein estimation: Determination of protein concentration 
for routine experiments such as monitoring of chromatographic 
columns; the protein concentration was determined by the 
method of Lowry et. al. (115) using Folin Phenol (116). 
Suitable aliquots of protein solutions were diluted to 1.0 ml 
of distilled water. To this was added 5.0 ml of freshly 
prepared copper reagent (prepared by mixing 1.07o (w/v) copper 
sulphate; 2.0% (w/v) sodium potassium tartarate and 2.0% 
(w/v) sodium carbonate in the ratio of 1:1:100 in O.IN sodium 
hydroxide). After incubtion at room temperature for 10 
minutes, 0.5 ml of IN Folin-Phenol reagent was added and the 
tubes were instantly vortexed. Absorbance of the blue colour 
was measured after 30 minutes at 660 nm against a reagent 
blank in a Bausch and Lamb spectronic 20 spectrophotometer. 
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Carbohydrate estimation 
The method used was that described by Dubois et.al. 
(1956) (117). To a 2.0 ml of sample containing appropriate 
quantity of protein in 20 mM phosphate buffer pH 7.5, 0.05 ml 
of 80% phenol solution was added. Five ml of cone. H SO, was 
^ 2 4 
subsequently added rapidly keeping stream of acid directed 
-gainst the liquid surface in order to get a good mixing. The 
tubes were allowed to stand for 10 minutes. They were then 
o 
vortexed and further Incubated at 30 C for 20 minutes. The 
absorbance of the yellow colour developed was measured at 
^HO nm against the blank. 
Polyacrylamlde gel electrophoresis 
PAGE was performed essentially, according to the method 
of Laemmli (118) using slab gel apparatus manufactured by 
Atto. Co. Japan. Concentrated stock solutions were mixed in 
appropriate order and proportions to give a final 
concentration of 157o acrylamide. It was then poured into the 
mold formed by two glass plates (7x9 cm) separated by 1.5 mm 
thick spacer. Bubbles and leaks was avoided. A comb providing 
a template for 12 sample wells were Inserted into the 
stacking gel solution before polymerization began. The 
polymerization was complete in about 2 hours. The comb was 
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removed and the wells thus formed were washed and overlaid 
with reservoir buffer. The samples for electrophoresis were 
prepared by mixing protein samples containing 25 ug with 
equal volume of sample buffer containing bromophenol blue 
and 10?o (w/v) sucrose were applied to the wells of the slab 
gel. Electrophoresis was carried out at 50 V for 
approximately 4 hours in tris-glycine reservoir buffer 
(0.0248 M tris and 0.192 M glycine) pH 8.3 till the tracking 
dye reached the bottom of the gel. After completion of the 
electrophoresis, the gels were immediately subjected to 
fixation and staining with Coomassie brilliant blue. The gels 
were treated with staining and destaining solutions in the 
following order. 
1. 0.17c Coomassie blue R-250 in 25% isopropanol and 10% 
glacial acetic acid for 2-4 hours. 
2. Destaining of the gels for several hours with 10% glacial 
acetic acid and 20% methanol until the blue background 
became clear. 
SDS Polyacrylamide gel electrophoresis 
SDS-PAGE was performed essentially according to the 
method of Laemmli (118) using a mini slab gel apparatus 
manufactured by Atto Co., Japan. It was used for the 
determination of subunit structure of the purified inhibitor. 
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The proteins were denaturated by treating 25 ug protein in 
0.02 M sodium phosphate buffer, pH 6.0 with 3.07o SDS and 
reduced with 5.07= of 2-mercaptoethanol, few drops of 107o 
(w/v) sucrose solution and 0.057, (w/v) bromophenol blue dye 
were added to the protein solution, which was then kept for 5 
o 
minutes at 100 C and then it was brought to room temperature. 
Protein solution were added on top of the freshly 
prepared 157, gel containing 0.6167, acrylamide and 
bisacrylamide, 0.027, SDS, 0.0057o (w/v) ammonium per sulphate, 
0.087o, v/v N,N,N,N tetramethylenediamine and 1.5 M tris-HCl 
buffer pH 8.8. 
Electrophoresis was carried out for 4 hours in 
trisglycine reservoir buffer (0.0248 M tris and 0.1'92 M 
glycine) pH 8.3 containing 17o (w/v) SDS by passing a current 
of 50 V. The gels were then stained with Coomassie blue for 1 
hour and destained mechanically in a mixture of 207, (v/v) 
methanol and 107=, (v/v) glacial acetic acid. 
Determination of proteinase activity 
Proteinase activity was determined using as substrate 
by the method of Kunitz (119) with slight modification. About 
40 ug of papain was taken in 0.4 ml of 0.01 M sodium 
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phosphate buffer pH 7.5 containing 0.05 M cysteine and 0.02 M 
EDTA was incubated for 5 minutes. The volume of reaction 
mixture was made 1.0 ml by the same buffer and then 1.0 ml of 
27o (w/v) of casein was added and reincubated for 30 minutes 
o 
at 37 C. The reaction was stopped by the addition of 1.0 ml 
of 107, (w/v) of trichloroacetic acid. After 15 minutes, tubes 
were centrifgued at 3000 x g for 10 minutes. An approximate 
amount of alliquot were developed by Lowry's procedure (115). 
The control was prepared in an identical manner except that 
casein was added 30 minutes after the addition of 
trichloroacetic acid and the blue colour was read at 660 nm. 
Thiol proteinase Inhibitor assay 
Thiol proteinase inhibitory activity was determined by 
measuring inhibition to the activity of papain. To 0.2 ml of 
papain (40 ug), 0.2 ml of activating agent (0.05 M cysteine 
and 0.02 M EDTA, pH 7.5) was added and incubated for 5 
o 
minutes at 37 C. An appropriate amount of fraction containing 
thiol proteinase inhibitor was added and the volume of the 
teaction mixture was made 1.0 ml with 0.02 M sodium phosphate 
o 
buffer,pH 7.5 and it was preincubated for 30 minutes at 37 C. 
To this 1.0 ml of reaction mixture, 1.0 ml of 2.07o (w/v) 
casein was added and then again incubated for 30 minutes at 
o 
37 C. Reaction was stopped by the addition of 1.0 ml of 107o 
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(w/v) trichloroacetic acid. After standing for an additional 
15 minutes, tubes were centrifuged at 3000 x g for 10 
minutes. An appropriate amount of aliquot from each test tube 
was developed by Folin-phenol reagent and the intensity of 
the blue colour was read at 660 nm against the reagent blank. 
The readings were corrected for blank solutions in which the 
reaction was stopped by 1.0 ml of 10% (w/v) trichloroacetic 
acid prior to the addition of 1.0 ml 2% (w/v) casein. 
Optical Measurements 
Ultraviolet absorption was measured on PU-8800 UV 
spectrophotometer (Pye Unicam) with a quartz cell of 1 cm 
path length. 
Photography 
Gels stained with Coomassie brilliant blue R-250 were 
photographed on ORWU Illumination. 
RESULTS 
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Purification of Cystatins from human placenta 
Purification of cystatin from human placenta was done 
by the modification of the method of M. Warwas and G.Sawiscki 
(113). Fresh placental tissue (200 gms) was homogenized in 
400 ml of mixture 1.0% NaCl/ 3 mM EDTA/ 2.0% N butanol for 
10 minutes in a Remi homogenizer. EDTA was used as chaelating 
o 
agent. The homogenate was centrifuged at 4.0 C. The residues 
was discarded and the pH of the supernatent was adjusted to 
o 
3.0 by acetic acid, then it was heated at 60 C for 10 minutes 
to remove some unwanted proteins. The pH of this solution was 
adjusted to pH 6.0 with 3M NaOH. The precipitate thus 
obtained was discarded. To this supernatent now equal volume 
of chilled acetone solution was added and left for 30 
minutes, the precipitate was dissolved overnight in 20 mM 
sodium phosphate buffer, pH 6.0 containing 0.15M NaCl. The 
dissolved precipitate was fractionated with various 
concentration of ammonium sulphate. The precipitate formed 
after 8 hour between 0-55% ammonium sulphate saturation 
having no thiol activity was discarded. The concentration of 
ammonium sulphate was then raised to 80% in the supernatent 
and was kept for 8 hours for precipitation. The precipitate 
was then collected by centrifugation at 1500 x g in Remi-C-24 
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cooling centrifuge for 30 minutes. It was dissolved in 20 mM 
sodium phosphate buffer pH 6.0 and dialyzed against 50 
volumes of the same buffer containing 0.15 NaCl. 
Sephadex GcQ.gQgel filtration 
The protein precipitated between 55-807<, saturation of 
ammonium sulphate after dialysis was applied on a column of 
Sephadex GTQ.QQ (2X90 cm) equilibrated with 20 mM sodium 
phosphate buffer, pH 6.0 containing 0,15 M NaCL. Fig (1) 
represents the elution profile of inhibitors on Sephadex G50-8O 
column. The inhibitory activity in every fraction toward 
papain was estimated using casein as substrate. Significant 
inhibitory activities were found in two peaks out of the 
three proteinpeaks (118). Fractions showing inhibitory 
activity against papain were then pooled, concentrated and 
dialyzed against 20 mM sodium phosphate buffer pH 6.0. Peak I 
and II (Fig. 1) thus purified had 3554 and 9805 fold 
purification respectively with a yield of 4.7% and 13.0% 
respectively. 
Homogeniety 
Homogeniety of the two papain inhibitory peaks were 
determined by polyacrylamide gel electrophorsis in the 
absence of SDS, The crude preparation fractionated with 55-
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80?o ammonium sulphate showed 3 bands in 157o acrylamide gel 
(Fig.2). The two papain inhibitory peaks obtained after 
Sephadex GCQ_OQ column were also applied on the same gel 
concentration in the absence of SDS and mercaptoethanol 
showed single band indicating the removal of impure proteins 
from each peaks (Fig. 2-). 
Molecular weight determination 
The molecular weight of the purified protein inhibitors 
were determined by gel filtration on Sephadex G(._ „„ as well 
as by PAGE performed in the presence of SDS and 
mercaptoethanol. For gel filtration study, 1.2x90 cm column 
was equilibrated with 20 mM sodium phosphate buffer, pH 6.0 
containing 0.15 M sodium chloride. The column was calibrated 
with bovine serum albumin, ovalbumin, soyabean trypsin 
inhibitors and 3.0 ml fraction were collected at a flow rate 
of 15 ml/hour. The elution profile of blue dextran market 
proteins and papain inhibitors are shown in Fig. (3)' The 
void volume (Vo) was calculated by measuring the effluent 
peak position of the blue dextram. A plot of Ve/Vo versus 
logarithm of molecular weight according to the procedure of 
Andrews (1964) gave a straight line Fig. (4). The molecular 
weight of peak I and II calculated from this plot came out to 
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be nearly 27,000 and 13,000 respectively. The 1st inhibitor 
peak was eluted as single peak with elution volume of 93 ml 
and Ilnd inhibitor had an elution volume of 110 ml. The void 
volume of the column was 47 ml. The gel filtration data were 
also analyzed by the method of least squares using the 
procedures of Laurent and Killander (121). 
Ve 
= 6.1838 - 0.9209 log M (1) 
Vo 
From this equation the values of the molecular weight of 1st 
and Ilnd inhibitor came out to be 31,000 and 13,000 
respectively. The average of the two values as determined by 
gel filtration plot and equation (1) turn out to be 29,000 
for 1st and 13,000 for Ilnd respectively. 
The molecular weight of both inhibitors were also 
determined by SDS-PAGE in presence and in absence of B 
mercaptoethanol at pH 8.3, using the marker proteins bovine 
serum albumin, ovalbumin, carbonic anhydrase and ribo 
nuclease (Fig. 5 & 6). A plot of log M versus relative 
mobility R (Fig. 7 ) gave a straight line fits the equation 
M 
(2) 
Log M = -1.29 R + 5.11 (2) 
M 
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The relative mobility of 1st and Ilnd inhibitors were 
determined (in presence of BME) to be 0.80. Which correspond 
to molecular weight nearly 13,000. This result now confirmed 
that 1st inhibitor consisted of two subunits of 13,000 each. 
While Ilnd inhibitor was single polypeptide. 
To determine the stokes radius of the dimer (peak I) 
and monomer (peak II) the data were processed using the 
following expression. The total volume of the column V was 
found to be 104 ml. 
K = (V - V ^) / (V. - V^ ) (3) 
av e o t o 
where K is the available distribution coefficient, 
av 
1/2 
(- log K^„) = 0.1885 r - 0.0366 (4) 
where r is the stokes radius 
The value of the stokes radius of dimer (inhibitor 
I), monomer (inhibitor II) as determined by equation (4) came 
out to be 2.45 and 1.90 respectively, (Fig. 8). The 
frictional ratio f/fp fo inhibitor 1st and Ilnd were also 
calculated with the help of the following equation 
37 
3 V2 M 
1/3 
F/Fo = r / ( ) 
4 7^: N 
Where "V2 ^s the partial specific volume of the protein 
assumed to be 0.725 gm/ml, rt is the molecular weight and N is 
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the Avogadro 's number (6.02 x 10 ). The frictional ratio of 
both inhibitors were determined to be 1.25 A" for 1st and 
I 
1.22 A for Ilnd respectively. (Table 5,6) 
Carbohydrate estimation 
Carbohydrate content determined by the method of Dubois 
et al (117) indicated the absence of carbohydrate moieties in 
the i nhi bi tors. 
pH stability 
Fig (9) illustrate that purified papain inhibitors were 
stable between pH 3.0 - 8.0. 
Thermostability 
(a) Fig. (10) illustrate that thiol proteinase inhibitors of 
peak 1st and Ilnd heated at pH 6.0 at various 
o 
temperatures (40-90 C). The peak Ilnd showed no changes 
in antipapain activity. However, peak 1st showed a 
o 
decrease in antipapain activity above 70 C. 
ACC No. 
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(b) Fig. (11) illustrate that when the two inhibitors were 
o 
heated at 80 C at pH 6.0 for various time intervals, the 
peak Ilnd was more stable as compared to 1st. 
Optical properties 
The UV spectra of two papain inhibitors from placenta 
were taken in the wave length region 250-320 nm as shown in 
Fig. (12). 
The papain, inhibitor and inhibitor-papain complex 
absorbed maximally near 279 nm. The inhibitor-papain complex 
of both inhibitors showed a considerable decrease in the 
absorbance to enzyme alone the decrease is more pronounced in 
dimer as compared to monomer. 
Fig. 1 
Chromatography of Cystatins of Sephadex GcQ_gQ 
170 mg/2.5 ml of the crude inhibitor (55-807, ammonium 
sulphate precipitated protein) was applied on a column of 
Sephadex G^Q.QQ (2.0 x 90 cm) equilibriated with 0.02 M 
sodium phosphate buffer, pH 6.0 containing 0.15 M sodium 
chloride. The column was eluted in 5.0 ml fractions at a 
flow rate of 25 ml/hour. Each fraction was assayed for 
antlpapaJn activity and protein concentration. 
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Fig. 2 
Polyacrylamlde Gel Electrophoresis of Cystatins 
The electrophoretic patterns of different preparations of 
cystatins in 157o gels without SDS are shown 25 ug of each 
preparation was el ect rophoresed on the slab gel at room 
temperature using a current 50V, 
LANE A 
LANE B 
LANE C 
Ammonium s u l p h a t e . CLifc 
Peak I 
Peak I I 
r"--
A B C 
Fig. 3 
Gel filtration profile of Standard protein and Cystatlns on 
'—; « 
Sephadex GCQ.OQ column 
4 mg of each of the marker proteins and 5 mg of peak 1st and 
peak Ilnd cystatlns were chromatographed on 2.0x90 cm. 
Column : of Sephadex GCQ_OQ equilibrated with 0.02M sodium 
phosphate buffer, pH 8.0 containing 0.15 sodium chloride* 
3.0 ml fractions were collected at a flow rate of 25 ml/ 
hour. Protein concentration were measured by the procedure 
of Lowry et. al (115 ) 
(A) BSA 
(B) Ovalbumin 
(C) -STI 
(D) Ribonuclease A 
(E) Peak I 
(F) Peak II 
^uo99 ID ao 
Fig.4 
Determination of Molecular weight of Cystatlns 
The data from Fig.2 was plotted as described by Andrews 
(1964). Void volume (Vo) was determined using blue dextran. 
The ..ratio of elution volume (Ve) to (Vo) was plotted against 
the logarithm of molecular weights of the marker proteins. 
(A) BSA 66 KD 
(B) Ovalbumin 44 KD 
(D) STI 24 KD 
(E) Ribonuclease 13.6 KD 
Position of cystatlns are indicated by C and| F respectively. 
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Fig. 6 
SDS Polyacryl amide Gel Electropho.t sis of Cyste tins 7f th 
standard proteins 
25 ug of each sample was subjected to electrophoresis ^n 
157o gel containing 0.27o SDS for 4 hours a'. 30V. '^ rior to 
electrophoresis, each sample was denaturated by heatirg aj 
100°C for 5 minutes with samples buffer containg |_-mercaptoetnanol. 
LANE A 
LANE B 
LANE C 
LANE D 
LANE E 
LAIfE F 
Bovine serum albumin (66 KD) 
Ovalbumin (44 KD) 
Carbonic anhydrase (29 KD) 
Ribonuclease (13.7 K0) 
Peak I 
Peak ri 
1 
A BCD E F 
Fig. 7 
Plot of relative mobility versus log M £or marker proteins 
In SDS-PAGE 
(Z>) BSA 66 KDa 
(C) Ovalbumin 44 KDa 
(B) Carbonic anhydrase 29 KDa 
(A) RibonOclease A 13,6 KDa 
RM of cystattns are indicated by arrow. The straight line 
obtained by the method of least squares fits the equation: 
Log M = -1.29 RM + 5.11 
5.0 r 
Fig. 8 
A Plot of stokes radius verses distribution coefficient 
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Fig. 9 
pH stability Profile 
The cystatlns were adjusted to various pH values (3,0-8.0) 
with 0.2 M phosphate and sodium acetate buffers and 
incubated for 20 hours at 4.0°C. The mixtures were then 
neutralized with some amount of the buffer of pH 7.5 and the 
remaining inhibitory activity was determined. 
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Fig. 10 
Heat Stability Profile 
Cystatins In 0.02 M phosphate buffer pH 6.0 were incubated 
at temperatures of 40-90°C for 30 minutes. The mixture were 
then cooled and the remaining inhibitory activity was 
determined (97). 
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Fig. 11 
Heat Stability Profile 
Cystatins in 0.02 M phosphate buffer pH 6.0 were incubated 
at 80°C for different times intervals. The mixture were then 
cooled and the remaining inhibitory activity was 
determined (97). 
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UV spectra of cystatln, papain and cystatln papain complex 
Cystatin : Peak I (200 ug/ml) 
Peak II (200 ug/ml) 
Papain (22 ug/ml) 
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DISCUSSION 
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In normal pregnancy as well as in many pregnancy 
associated disorders, placenta plays highly significant 
role (106). Lysosomes present in the cells of placenta take 
part in the intracellular degradation of proteins (4). 
Among the lysosomal enzymes cathepsins B,H,L and C 
constitute an important group of both endo and exopeptidases 
(74). These enzymes are inhibited by proteinase inhibitors 
named as cystatins. 
Cystatins are the proteins which specifically inhibit 
thiol proteinases. They are non-glycosylated proteins of 
molecular weight 11-13 KD and very stable toward pH and 
heat (75). These inhibitors are believed to be involved in 
the prevention of unwanted proteolysis. However specific 
biological functions of cystatins in placenta are yet 
unknown. Most of the physiological function assigned to the 
placental cystatins are based on framgentary data or are 
speculative therefore a specific search for biological 
(106-108). 
In view of importance of placental tissue and lack of 
information regarding structure and physiological role of 
cystatins, this inhibitor have been purified and 
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characterized from this tissue which is a pre-requisite for 
studying this inhibitor in great detail. 
Recently cystatins from human placenta have been 
partially purified by W.Warwas and G.Sawicki (113) using 
several purification steps including affinity chromatography 
on CM-papain sepharose 4B. They obtained two peaks of the 
inhibitor i.e. dimer of a molecular weight 26 KD and a 
monomer of 13 KD, the yield and fold purification for dimer 
was very low. Neither dimer nor monomer has been 
systematically characterized yet. 
The systematic procedure used in this study for the 
isolation and purification of cystatins (type II) from human 
placenta turned out to be superior to that reported in 
literature (112). The procedure used in the present work is 
a modification of the method of Warwas et al (113). A change 
of pH from 11.0 to 3.0, acetone fractionation and additional 
step of ammonium sulphate cut (55 - 80%) and sephadex G(-Q_nQ 
gel chromatography gave two molecular forms of cystatins 
with high yield and fold purification. 
The yield and fold purification for dimer was found to 
be 4.7% and 3554 respectively as compared to 0.7% and 1775 
values reported in literature (113) (Table 4). For monomer 
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same yield (137o) was obtained with a slightly high fold 
purification. Both of thetn were purified to a functionally 
pure state as indicated by the results of polyacrylamide gel 
electrophoresi s. 
The molecular weight of cystatins under native 
conditions by gel chromatography were found to be 29 KD for 
peak I and 13KD for peak II respectively. The molecular 
weight of cystatins when determined by PAGE under 
denaturating conditions was found to be 26 KD and 13 KD for 
peak I and II respectively in the absence of R-mercaptoethanol. 
Whereas in the presence of B -mercaptoethanol both had 
molecular weight of 13 KD. These results when taken together 
showed that the cystatins peak I was made up of two 
polypeptide chains of identical size that were held together 
by covalent bonds. Cystatin peak 11 was the monomer. 
All the well characterized cystatins from other tissue 
of different sourcesexhibit molecular weight in the range of 
11 KD - 14 KD. Dimers have also been reported in different 
tissues (40 - 50). 
Some properties of cystatins investigated in this 
study are listed in table 6. Hydrodynamic parameters of 
cystatins as determined from its gel filtration behaviour 
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from calibrated sephadex G^Q_gQ column suggested a stokes 
radius of 2.45 for dimer and 1.90 for monomer respectively. 
These values were used to compute the value of frlctional 
ratio (F/Fo) as described in results. Came out 
to be 1.25 for dimer and 1.22 for monomer. This 
indicates the deviation of dimer as well as monomer from 
globular shape. This assymetry of both inhibitors can be 
explained in two ways. Either both molecules were not 
spherical or it were excessively hydrated. 
The pH activity profile was not effected by the 
presence of inhibitor and it was found to be stable pH range 
3.0 - 8.0. pH results very much coincide with those reported 
by previous workers (71). Thermal results were also quite 
close to that reported by previous workers in other tissues 
Dimer was stable upto 70°C and monomer was stable upto 90°C 
indicating the presence of more hydrophobic residues and 
disulphide bonds. When the inhibitors were exposed at 80°C 
for different time Intervals again monomer was found to be 
more stable as compared to dimer. 
Both inhibitors were found to be non-glycosylated 
proteins which fits them well in the category of type II 
cystatin superfamily. 
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Fig. 12 shows the UV spectra of inhibitor in the 
presence and absence of papain. The results indicated that 
a conformational change occurs when the inhibitor combines 
with papain showing an involvement of chromophoric groups. 
The effect is more pronounced in monomer as compared to 
dimer. 
Since most of the other placental protein reported in 
literature are analogues of protein present in various other 
tissues of the normal adult. 
The monomer and dimer both need to be characterized in 
greater detail with respect to molecular and immunological 
properties. Then it will be worth while to compare the 
properties of placental cystatin with cystatins of other 
ti ssues. 
hitlHllafei 
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Table 1 
Compositions of some cystatins 
Cystatin A Cystatin B Cystatin C Cystatin S Chicken 
cystatin 
Cys 
Ser 
Thr 
Pro 
Ala 
Gly 
Asp 
Asp 
Glu 
Gin 
His 
Arg 
Lys 
Met 
He 
Leu 
Val 
Phe 
Tyr 
Trp 
Total 
residues 
-
2 
7 
5 
5 
8 
5 
6 
9 
6 
1 
1 
12 
2 
4 
8 
9 
2 
6 
-
98 
10992 
1 
6 
7 
5 
8 
3 
5 
4 
6 
7 
5 
2 
9 
2 
2 
6 
9 
7 
4 
-
98 
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Table 2 
List of Proteinases inhibited by cystatins superfamily 
Name of Cystatins Name of the proteinases inhibited by 
cystatins 
Type 1 
Cystatin A 
Cystatin B 
Papain, Ficin and human calhepsins 
B J C J H & L . 
Papain, Fincin and cathepsins B,C,H 
& L. 
Type 2 
Cystatin C 
Cystatin S 
Chicken cystatin 
Papain, Fincin and cathepsins B,C,H, 
& L. 
Papain and ficin 
Papain, Chymopapain, papaya proteinase 
III, actinidin and cathepsin B,C,H,L, 
N and C. 
Type 3 
Kininogen Papain, calpains and cathepsins 
B,C,H,L & N. 
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Table 3 
Kl values for Inhibition of thiol proteinases by low Mr cystatlns 
Human 
Cystatin A Cystatin B Cystatln C Chicken 
cystatin 
Papain 0.019 
Cathepsin B 8.2 
Cathepsin H 0.31 
Cathepsin L 1.3 
Dipeptidyl 
peptidase I 
33 
0.12 
73 
0.58 
0.23 
0.23 
0.005 0.005 
0.25 
0.28 
3.5 
1.7 
0.064 
0.005 0.019 
0.35 
59 
I—I 
« 
C 
o 
u 
03 
>-• 
o 
c 
a 
a 
u 
CO 
o 
c 
o 
•H 
« 
u 
• l l 
•r-( 
v< 
3 
-o 1—t 
0 
fc, 
c 
o 
• r i 
• l - l 
TO 
O 
•1-1 
U-l 
•l-t 
u 3 
a 
o >, 
( 1 ) . — I 
•u e 
>-. CO 
a, E 
c 
CN 
T H 
CSI 
<J-
i n 
LO 
n 
i n 
o 
0 0 
0 ^ 
cu 
•rt B^ 
>' 
o 
o 
T-l 
o 
cr. 
vO 
CO 
O 
OJ 
CO 
Ll-I .rt 
•« > 
O -r-i 
(U -U 
a. u 
en < 
0 0 
^£) 
o 
o 
• 
o 
vO 
vJ-
t H 
o 
• 
o 
0 0 
0 0 
0 0 
• 
o 
vO 
< ! • 
• 
i-M 
o 
c 
E 
t—I 
O 
> 
o 
00 
00 
en 
in 
in 
o 
i n 
<r 
• 
cs 
CN 
VO 
VD 
• 
vO 
v^ 
00 o 
CO 
o 
o 
CN 
CM 
O 
O 
CN 
O 
0 0 
<)• 
>0-
vO 
in 
o 
<3^ 
O 
O 
CO 
o 
CN 
o 
o 
•<)• 
•u 
o 
CO 
)-
4J 
X 
OJ 
1—1 
CO 
•P 
c 
0) 
o CO 
.—1 
a. 
m 
i n 
CO 
o 
• 
\D 
X 
a 
o 
in 
c 
o 
•H 
•U 
CO 
C 
o 
•r-l 
•U 
o 
CO 
u 
u-l 
(U 
c 
o 
•u 
0) 
o 
< 
o 
CO 
cu 
•u 
CO 
X. 
a c 
r—1 
3 
cn 
E 
D 
•r-t 
c 
o 
E 
E 
o 
• H 
u 
CO 
c 
o 
• H 
4J 
o 
CO 
t-
< LH 
o 
0 0 
1 
o 
i n 
o 
X 
cu 
T3 
CO 
^ 
a 
cu 
CO 
i n 
T-l 
4J 
cn 
M 
^ 
CO 
(U 
Cl-
i n 
t H 
X) 
c 
M 
M 
^ 
CO 
cu 
Q-
60 
m 
(U 
I—I 
W3 
C 
. 1 - 4 
i) 
o 
a 
<^ 
o 
4J 
• IH 
X) 
•r- l 
x: 
c 
•i-i 
T5 
C 
CO 
c 
o 
re 
CM 
60 
3 
c 
•H 
0 
k< 
a 
u 
re 
o 
VH 
(/} 
U 
Q) 
i J 
0) 
E 
« 
re 
a 
re 
1—I 
o 
o 
CNJ 
> 
re 
00 
o 
I 
> 
re 
CO 
T- l 
o 
> 
> 
U3 
0) 
o 
O O 
o 
re 
I—I 
a; 00 
1—1 - H 
o cu 
S 3 
•U 
O )-> 
CSJ 
CN 
CSI 
ON 
vO 
n 
CM 
r^ 
< » • 
ON 
vO 
m 
ON 
vO 
CO 
CM 
CM 
CM 
CO 
CN 
O 
CJN 
o 
CO 
CJN 
0 0 
r H 
CO 
r^ 
CJN 
CJN 
m 
<f 
(-^  
< } • 
T H 
CO 
r^ 
o 
i n 
0 0 
CM 
C3N 
CO 
CN 
0 0 
0 0 
CM 
o 
CO 
i n 
CO 
o 
CM 
ON 
CNJ 
i n 
CO 
CM 
CM 
CM 
O 
CO 
CM 
00 
CO 
C M 
<3N 
in 
CO in 
m 
CM CO 
00 
o 
o • < ( • 
Cvl 
m 
(N 
o 
CJN 
ONJ 
r^ 
CO 
T H 
-sJ-
CM 
<1-
< t 
vO 
NO 
vO 
CM 
CO 
(U 
en 
re 
OJ 
1—1 
o 
D 
C 
O 
Xi 
•r-l 
a 
>^  
u 
u 
U 
c o 
re 4-> 
<U - i - i 
X J X i 
re T-t 
>,x; 
o c 
c 
• H 
e 
0 
XI 
1—1 
re 
> 
E 
D )-. 
CU 
• en 
c (U -H 
C E 
•H D 
> X I 
O i - i 
c 
•H >-. 
re o 
cxu 
re .1-4 
CL, X ) 
.1-1 
u x l 
W C 
c 
•1-1 
re V-
a o 
re x j 
a - H 
XI 
X) -H 
c x; M C 
OS CO . H CO re 
61 
Table 6 
Some properties of Cystatlns (type II) 
Properties Values of Values of 
dimer monomer 
1. Molecular mass by gel 29 13 
filtration (KD) 
2. Molecular mass by SDS-PAGE 26 13 
3. Molecular mass by SDS-PAGE 13 13 
in presence of B mercaptoethanol 
4. Stokes radius (nm) 2.45 1.90 
5. Fractional ratio 1.25 1.22 
6. Carbohydrate content Nil Nil 
7. Absorption maximum (nm) 278 278 
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